Sandostatin LAR®: Pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients
- 31 January 1995
- journal article
- Published by Elsevier in Metabolism
- Vol. 44, 18-26
- https://doi.org/10.1016/0026-0495(95)90306-2
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Resistance to Somatostatin (SRIH) Analog Therapy in AcromegalyHormone Research, 1992
- Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study GroupArchives of internal medicine (1960), 1991
- Long Term Effect of Incremental Doses of the Somatostatin Analog SMS 201–995 in 58 Acromegalic Patients*Journal of Clinical Endocrinology & Metabolism, 1990
- A Randomized Study of SMS 201–995VersusBromocriptine Treatment in Acromegaly: Clinical and Biochemical EffectsJournal of Clinical Endocrinology & Metabolism, 1990
- The Growth Hormone Responses to Octreotide in Acromegaly Correlate with Adenoma Somatostatin Receptor StatusJournal of Clinical Endocrinology & Metabolism, 1989
- Somatostatin Receptors in Normal and Tumoral TissueHormone Research, 1988
- The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegalyActa Endocrinologica, 1987
- Medical Treatment of Acromegaly with SMS 201-995, a Somatostatin Analog: A Comparison with Bromocriptine*Journal of Clinical Endocrinology & Metabolism, 1987
- Plasma Growth Hormone Responses to Somatostatin (SRIH) and SRIH Receptors in Pituitary Adenomas in Acromegalic Patients*Journal of Clinical Endocrinology & Metabolism, 1986
- Specific Somatostatin Receptors on Human Pituitary Adenoma Cell Membranes*Journal of Clinical Endocrinology & Metabolism, 1985